The present invention relates to a compound which is (2R,3R,4S,5R)-2-(6-amino-2-{[(1S)-2-hydroxy-1-(phenylmethyl)ethyl]amino}-9H-purin-9-yl)-5-(2-ethyl-2H-tetrazol-5-yl)tetrahydro-3,4-furandiolor a pharmaceutically acceptable salt thereof for use in the treatment or prevention of inflammatory and non-inflammatory diseases abd conditions associated with alveolar filling.
